Laura C. Coates

Nuffield Orthopaedic Centre — United Kingdom

Medicine · Health Sciences

67h-index18.6kcitations767works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Spondyloarthritis Studies and Treatments(556), Psoriasis: Treatment and Pathogenesis(455), Rheumatoid Arthritis Research and Therapies(388), Autoimmune and Inflammatory Disorders Research(260), Health Systems, Economic Evaluations, Quality of Life(40)

Publications760 total

The path to interception in psoriatic disease: from conceptual clarity to clinical translation
The Lancet Rheumatology·2026
Trialblazers: patient-driven redesign of a clinical trial in psoriatic arthritis
The Lancet Rheumatology·2026
Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study
Seminars in Arthritis and Rheumatism·2025Open Access
Therapeutic Windows Across the Psoriatic Arthritis Spectrum
Rheumatology and Therapy·2025Open Access
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials
Rheumatology and Therapy·2025Open Access
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab
The Journal of Rheumatology·2025Open Access
Stratégie du traitement à la cible dans le rhumatisme psoriasique en vraie vie : résultats à 48 semaines de la cohorte MONITOR-PsA
Revue du Rhumatisme·2025
Key factors contributing to gender inequity in global rheumatology awards: a global survey analysis
Lara D. Veeken·2025· 2 cited
A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK
Lara D. Veeken·2025Open Access
331 Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results From APEX
Journal of Investigative Dermatology·2025
204 Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b APEX Study
Journal of Investigative Dermatology·2025
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter
Clinical Pharmacology & Therapeutics·2025
Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs
2025Open Access
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial
Nature Medicine·2025· 3 citedOpen Access
S1663 Inhibition of Structural Damage Progression With Guselkumab in Participants With Active Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
The American Journal of Gastroenterology·2025
PASDAS test–retest reliability in early, untreated PsA: data from the GOLMePsA clinical trial
Lara D. Veeken·2025
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study
Annals of the Rheumatic Diseases·2025· 1 citedOpen Access
Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years
Lara D. Veeken·2025Open Access
Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial
The Lancet Rheumatology·2025· 3 cited
61877 Integrated Interval Analysis of Clinical Trial Data to Evaluate the Long-Term Safety of Risankizumab in Patients With Psoriatic Disease
Journal of the American Academy of Dermatology·2025
page 1 of 38Next →

Frequent Co-authors

Philip Helliwell(21), Dafna D. Gladman(14), Philip J. Mease(13), Oliver FitzGerald(12), Alexis Ogdie(11), Paul Emery(10), Philip G. Conaghan(9), Neil McHugh(8), Alice B. Gottlieb(7), Laure Gossec(7), Christopher T. Ritchlin(6), Maarten de Wit(6), E. Hensor(6), Arthur Kavanaugh(5), M. Elaine Husni(5), Ana‐Maria Orbai(5), Ying Ying Leung(5), Joseph F. Merola(5), William Tillett(5), Catherine Smith(5)